<p><strong>Bionano Genomics, Inc.</strong>（纳斯达克代码：BNGO）的股东们会很高兴地看到，股价在过去一个月表现出色，上涨了 28%，并从之前的疲软中恢复过来。但上个月的表现对过去一年 85% 的股价下跌几乎没有改善。</p>
<p>即使在如此大幅的价格上涨之后，Bionano Genomics 目前仍可能发出非常看涨的信号，其市销率（&#34;P/S&#34;）为 0.7 倍，因为美国生命科学行业几乎一半的公司市销率超过 3.2 倍，甚至市销率超过 7 倍的情况也并不罕见。不过，我们需要更深入地探讨，以确定这种大幅降低的市销率是否有合理的基础。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>查看我们对 Bionano Genomics 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551"/></p>
<p>纳斯达克 CM:BNGO 市销率与行业比较 2025 年 9 月 14 日</p>
<h3>Bionano Genomics 最近的表现如何？</h3>
<p>Bionano Genomics 最近的表现不佳，其收入下降与其他公司相比显得相形见绌，后者的收入平均有所增长。市销率之所以可能较低，是因为投资者认为这种糟糕的收入表现不会有所改善。如果你仍然喜欢这家公司，你会希望情况并非如此，以便在它不受欢迎时能够潜在地买入一些股票。</p>
<p>想知道分析师如何看待 Bionano Genomics 的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
<h2>收入增长指标告诉我们关于低市销率的什么？</h2>
<p>你唯一会真正感到舒适的情况是，当 Bionano Genomics 的市销率如此低迷时，公司的增长显然落后于行业。</p>
<p>首先回顾一下，去年公司的收入增长并不令人兴奋，出现了令人失望的 25% 的下降。这对其长期以来的良好表现造成了影响，因为其三年总收入增长仍然值得关注，达到了 18%。因此，我们可以首先确认，该公司在这段时间内总体上在收入增长方面做得不错，尽管过程中有一些波折。</p>
<p>展望未来，预计未来三年每年的增长率将达到 29%，这是由两位关注该公司的分析师估算的。这一增长率显著高于更广泛行业的 7.0% 年增长预测。</p>
<p>根据这些信息，我们发现 Bionano Genomics 的市销率低于行业水平，这一点令人费解。看起来大多数投资者并不相信该公司能够实现未来的增长预期。</p>
<h2>最终结论</h2>
<p>尽管 Bionano Genomics 的股票价格显著上涨，但其市销率仍然处于低迷状态。有人认为，在某些行业中，市销率是一个较差的价值衡量标准，但它可以是一个强有力的商业情绪指标。</p>
<p>在我们看来，Bionano Genomics 目前的市销率显著低于其预期的收入增长，这一增长高于其行业的其他公司。可能存在一些重大风险因素对市销率施加下行压力。尽管由于公司预期的高增长，股价暴跌的可能性似乎不大，但市场确实表现出一些犹豫。</p>
<p>那么其他风险呢？每家公司都有风险，我们发现了 <strong>Bionano Genomics 的 4 个警告信号</strong>（其中 1 个有点不愉快！）你应该了解。</p>
<p><strong>如果你对过去盈利增长稳健的公司感兴趣</strong>，你可能希望查看这份 <strong>免费</strong> 的其他强劲盈利增长和低市盈率公司的集合。</p>

BNGO

<p>Bionano Genomics, Inc.（纳斯达克股票代码：BNGO）的股价最近上涨了 28%，从过去一年显著下跌的 85% 中恢复过来。尽管有这一涨幅，该公司的市销率（P/S）仍然较低，为 0.7 倍，而行业平均水平为 3.2 倍。该公司的收入在去年下降了 25%，但分析师预测未来三年年均增长 29%，高于行业平均的 7%。市场似乎对 Bionano 的增长潜力持怀疑态度，导致其市销率低迷，尽管增长预测积极</p>

<p><strong>Bionano Genomics, Inc.</strong> (NASDAQ:BNGO) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. But the last month did very little to improve the 85% share price decline over the last year.</p>
<div class="lb-trans"><p><strong>Bionano Genomics, Inc.</strong>（纳斯达克代码：BNGO）的股东们会很高兴地看到，股价在过去一个月表现出色，上涨了 28%，并从之前的疲软中恢复过来。但上个月的表现对过去一年 85% 的股价下跌几乎没有改善。</p>
</div><p>Even after such a large jump in price, Bionano Genomics may still be sending very bullish signals at the moment with its price-to-sales (or &#34;P/S&#34;) ratio of 0.7x, since almost half of all companies in the Life Sciences industry in the United States have P/S ratios greater than 3.2x and even P/S higher than 7x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.</p>
<div class="lb-trans"><p>即使在如此大幅的价格上涨之后，Bionano Genomics 目前仍可能发出非常看涨的信号，其市销率（&#34;P/S&#34;）为 0.7 倍，因为美国生命科学行业几乎一半的公司市销率超过 3.2 倍，甚至市销率超过 7 倍的情况也并不罕见。不过，我们需要更深入地探讨，以确定这种大幅降低的市销率是否有合理的基础。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>Check out our latest analysis for Bionano Genomics</p>
<div class="lb-trans"><p>查看我们对 Bionano Genomics 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551" alt="" original-src="https://images.simplywall.st/asset/chart/5900432-ps-multiple-vs-industry-1-dark-2/1757855588551"/></p>
<p>NasdaqCM:BNGO Price to Sales Ratio vs Industry September 14th 2025</p>
<div class="lb-trans"><p>纳斯达克 CM:BNGO 市销率与行业比较 2025 年 9 月 14 日</p>
</div><h3>How Has Bionano Genomics Performed Recently?</h3>
<div class="lb-trans"><h3>Bionano Genomics 最近的表现如何？</h3>
</div><p>Bionano Genomics hasn't been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>Bionano Genomics 最近的表现不佳，其收入下降与其他公司相比显得相形见绌，后者的收入平均有所增长。市销率之所以可能较低，是因为投资者认为这种糟糕的收入表现不会有所改善。如果你仍然喜欢这家公司，你会希望情况并非如此，以便在它不受欢迎时能够潜在地买入一些股票。</p>
</div><p>Keen to find out how analysts think Bionano Genomics' future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析师如何看待 Bionano Genomics 的未来与行业的对比吗？在这种情况下，我们的 <strong>免费</strong> 报告是一个很好的起点。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于低市销率的什么？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as depressed as Bionano Genomics' is when the company's growth is on track to lag the industry decidedly.</p>
<div class="lb-trans"><p>你唯一会真正感到舒适的情况是，当 Bionano Genomics 的市销率如此低迷时，公司的增长显然落后于行业。</p>
</div><p>Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 25%. That put a dampener on the good run it was having over the longer-term as its three-year revenue growth is still a noteworthy 18% in total. So we can start by confirming that the company has generally done a good job of growing revenue over that time, even though it had some hiccups along the way.</p>
<div class="lb-trans"><p>首先回顾一下，去年公司的收入增长并不令人兴奋，出现了令人失望的 25% 的下降。这对其长期以来的良好表现造成了影响，因为其三年总收入增长仍然值得关注，达到了 18%。因此，我们可以首先确认，该公司在这段时间内总体上在收入增长方面做得不错，尽管过程中有一些波折。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 29% each year as estimated by the dual analysts watching the company. That's shaping up to be materially higher than the 7.0% per year growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未来，预计未来三年每年的增长率将达到 29%，这是由两位关注该公司的分析师估算的。这一增长率显著高于更广泛行业的 7.0% 年增长预测。</p>
</div><p>With this information, we find it odd that Bionano Genomics is trading at a P/S lower than the industry. It looks like most investors are not convinced at all that the company can achieve future growth expectations.</p>
<div class="lb-trans"><p>根据这些信息，我们发现 Bionano Genomics 的市销率低于行业水平，这一点令人费解。看起来大多数投资者并不相信该公司能够实现未来的增长预期。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最终结论</h2>
</div><p>Shares in Bionano Genomics have risen appreciably however, its P/S is still subdued. It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.</p>
<div class="lb-trans"><p>尽管 Bionano Genomics 的股票价格显著上涨，但其市销率仍然处于低迷状态。有人认为，在某些行业中，市销率是一个较差的价值衡量标准，但它可以是一个强有力的商业情绪指标。</p>
</div><p>To us, it seems Bionano Genomics currently trades on a significantly depressed P/S given its forecasted revenue growth is higher than the rest of its industry. There could be some major risk factors that are placing downward pressure on the P/S ratio. While the possibility of the share price plunging seems unlikely due to the high growth forecasted for the company, the market does appear to have some hesitation.</p>
<div class="lb-trans"><p>在我们看来，Bionano Genomics 目前的市销率显著低于其预期的收入增长，这一增长高于其行业的其他公司。可能存在一些重大风险因素对市销率施加下行压力。尽管由于公司预期的高增长，股价暴跌的可能性似乎不大，但市场确实表现出一些犹豫。</p>
</div><p>And what about other risks? Every company has them, and we've spotted <strong>4 warning signs for Bionano Genomics</strong> (of which 1 is a bit unpleasant!) you should know about.</p>
<div class="lb-trans"><p>那么其他风险呢？每家公司都有风险，我们发现了 <strong>Bionano Genomics 的 4 个警告信号</strong>（其中 1 个有点不愉快！）你应该了解。</p>
</div><p><strong>If companies with solid past earnings growth is up your alley</strong>, you may wish to see this <strong>free</strong> collection of other companies with strong earnings growth and low P/E ratios.</p>
<div class="lb-trans"><p><strong>如果你对过去盈利增长稳健的公司感兴趣</strong>，你可能希望查看这份 <strong>免费</strong> 的其他强劲盈利增长和低市盈率公司的集合。</p>
</div>

Bionano Genomics, Inc.（纳斯达克代码：BNGO）股价上涨 28% 背后缺失的一块拼图